Skip to content

ONCORADIOMICS

Active
Public limited companyfounded 201610 yrs activeBoulevard de Patience et Beaujonc 3, 4000 Liège, BelgiumKBO/BCE: BE 0662.719.440
Summary

ONCORADIOMICS has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-4k) and a net result of €285k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 14% of 191 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Checked score

Score 2025
Axes · tick = 2024
Profitability77▲+77
Solvency25▲+25
Growth78▲+26
Track record100
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.35 against 0.7 in 2024; short-term debt: 79.2% and cash: 0.2% of total assets), and equity is negative.
Credit check for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies more bankruptcies →
lowers risk · Lower-risk legal form
Companies with this legal form statistically fail less often than a BV.
KBO · legal form
raises risk · Higher-failure-rate region
In this region companies fail more often than in the rest of the country.
KBO · registered office
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025
Solvency, return and age of the figures
Solvency
-0.1%
Return on assets
6.6%
Age of the figures
9 mo
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 14% of 191 sector peers (2025).
NBB · sector comparison
Position among 191 sector peers
Solvency
better than 14%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 9 filings
Deviation from the deadline
2025
28 d early
2024
186 d late
2023
5 d late
2022
21 d early
2021
37 d late
2020
2 d early
2019
16 d early
← before the deadline after the deadline →
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven months
Position in the running window
25-09-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
€285k
2024 · €-1.15M
2018: €-840k 2019: €-729k▲ +13.1% vs 2018 2020: €-720k▲ +1.2% vs 2019 2021: €-1.48M▼ -105% vs 2020 2022: €-2.37M▼ -60.3% vs 2021lowest in 8 years 2023: €-1.90M▲ +19.6% vs 2022 2024: €-1.15M▲ +39.5% vs 2023 2025: €285k▲ +125% vs 2024highest in 8 years
2018 → 2025
Working capital
€-2.22M▼ 158%
2024 · €-860k
2018: €1.38M 2019: €893k▼ -35.5% vs 2018 2020: €3.18M▲ +257% vs 2019 2021: €3.62M▲ +13.8% vs 2020highest in 8 years 2022: €1.33M▼ -63.3% vs 2021 2023: €-594k▼ -145% vs 2022 2024: €-860k▼ -44.8% vs 2023 2025: €-2.22M▼ -158% vs 2024lowest in 8 years
2018 → 2025
Trend over the years
Multi-year overview
Every figure with its change against the year before
▲ rise ▼ fall
Line20212022202320242025Trend
Equity€410k-€-1.76M€-3.61M▼ 106%€-1.02M▲ 71.7%€-4k▲ 99.6% 2021: €410khighest in 5 years 2022: €-1.76M▼ -528% vs 2021 2023: €-3.61M▼ -106% vs 2022lowest in 5 years 2024: €-1.02M▲ +71.7% vs 2023 2025: €-4k▲ +99.6% vs 2024
Operating result€-1.48M-€-2.30M▼ 55.6%€-1.75M▲ 24.2%€-983k▲ 43.7%€410k 2021: €-1.48M 2022: €-2.30M▼ -55.6% vs 2021lowest in 5 years 2023: €-1.75M▲ +24.2% vs 2022 2024: €-983k▲ +43.7% vs 2023 2025: €410k▲ +142% vs 2024highest in 5 years
Net result€-1.48M-€-2.37M▼ 60.3%€-1.90M▲ 19.6%€-1.15M▲ 39.5%€285k 2021: €-1.48M 2022: €-2.37M▼ -60.3% vs 2021lowest in 5 years 2023: €-1.90M▲ +19.6% vs 2022 2024: €-1.15M▲ +39.5% vs 2023 2025: €285k▲ +125% vs 2024highest in 5 years
Result per fiscal year
Operating resultNet result
€-3.00M€-2.00M€-1.00M€0Operating result 2021: €-1.48M€-1.48MNet result 2021: €-1.48M€-1.48MOperating result 2022: €-2.30M€-2.30MNet result 2022: €-2.37M€-2.37MOperating result 2023: €-1.75M€-1.75MNet result 2023: €-1.90M€-1.90MOperating result 2024: €-983k€-983kNet result 2024: €-1.15M€-1.15MOperating result 2025: €410k€410kNet result 2025: €285k€285k20212022202320242025€-2M€-1M€0Operating result 2023: €-1.75M€-1.7MNet result 2023: €-1.90M€-1.9MOperating result 2024: €-983k€-983kNet result 2024: €-1.15M€-1.2MOperating result 2025: €410k€410kNet result 2025: €285k€285k202320242025
The operating result returns to profit in 2025: €410k after a loss of €983k in 2024, the highest result in the available series.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €4.31M
Fixed assets €3.11M ▲ 71.7%
Current assets €1.19M ▼ 40.0%
Key figures and ratios
2025 value · change against 2024
EBITDA
€858k▲
2024 · €-302k
Cash flow
€732k▲
2024 · €-470k
Solvency
-0.1%▲
2024 · -26.9%
Current ratio
0.35▼
2024 · 0.70
ROA
6.6%▲
2024 · -30.3%
Interest coverage
6.72▲
2024 · -1.66
Debt
€4.31M▼
2024 · €4.82M
Debt ≤ 1 year
€3.41M▲
2024 · €2.85M
Debt > 1 year
€769k▼
2024 · €1.40M
Income taxes
€0▲
2024 · €-12k
Staff costs
€1.51M▼
2024 · €1.56M
A ratio outside any meaningful range has been withheld (balance sheet total €4.31M, equity €-4k).
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Filed annual accounts As filed with the NBB · 2025 against 2024 · 53 lines
Balance sheet Code20242025
Assets
Total assets20/58€3.80M€4.31M▲
Fixed assets21/28€1.81M€3.11M▲
Intangible fixed assets21€1.70M€3.03M▲
Tangible fixed assets22/27€37k€14k▼
Furniture and vehicles24€32k€12k▼
Other tangible fixed assets26€5k€2k▼
Financial fixed assets28€71k€71k=
Current assets29/58€1.99M€1.19M▼
Amounts receivable within one year40/41€845k€1.15M▲
Trade receivables40€556k€672k▲
Other amounts receivable41€289k€480k▲
Cash at bank and in hand54/58€1.00M€9k▼
Deferred charges and accrued income490/1€138k€32k▼
Equity and liabilities
Total equity and liabilities10/49€3.80M€4.31M▲
Equity10/15€-1.02M€-4k▲
Contributions10/11€3.47M€3.47M=
Capital10€270k€270k=
Issued capital100€270k€270k=
Outside capital11€3.20M€3.20M=
Share premium1100/10€3.20M€3.20M=
Profit (loss) carried forward14€-5.42M€-5.14M▲
Investment grants15€929k€1.66M▲
Amounts payable17/49€4.82M€4.31M▼
Amounts payable after more than one year17€1.40M€769k▼
Financial debts170/4€1.40M€769k▼
Amounts payable within one year42/48€2.85M€3.41M▲
Current portion of amounts payable after more than one year42€162k€221k▲
Financial debts43€2.00M€2.04M▲
Credit institutions430/8€2.00M€1.69M▼
Other loans439-€350k
Trade debts44€525k€1.02M▲
Suppliers440/4€525k€1.02M▲
Taxes, remuneration and social security45€159k€130k▼
Taxes450/3€2k€1k▼
Remuneration and social security454/9€157k€129k▼
Accrued charges and deferred income492/3€573k€130k▼
Income statement Code20242025
Remuneration, social security and pensions62€1.56M€1.51M▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€682k€448k▼
Other operating charges640/8€2k€20▼
Non-recurring operating charges66A€0€3k▲
Gross operating margin9900€1.26M€2.37M▲
Operating profit (loss)9901€-983k€410k▲
Financial income75/76B€909€2k▲
Recurring financial income75€909€2k▲
Financial charges65/66B€181k€128k▼
Recurring financial charges65€181k€128k▼
Profit (loss) for the period before taxes9903€-1.16M€285k▲
Income taxes67/77€-12k€0▲
Profit (loss) for the period9904€-1.15M€285k▲
Profit (loss) for the period to be appropriated9905€-1.15M€285k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-5.42M€-5.14M▲
Profit (loss) brought forward from the previous period14P€-4.27M€-5.42M▼
Social balance
Average headcount (FTE)908723.720.2▼

The notes to these accounts (24 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Accounts by statement
Line20212022202320242025Change
Remuneration, social security and pensions62€1.45M€1.72M€1.78M€1.56M€1.51M▼ 3.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€1.51M€893k€827k€682k€448k▼ 34.3%
Other operating charges640/8€5k€1k€2k€2k€20▼ 99.0%
Non-recurring operating charges66A€4k€5k€11k€0€3k-
Gross operating margin9900€1.48M€311k€877k€1.26M€2.37M▲ 87.8%
Operating profit (loss)9901€-1.48M€-2.30M€-1.75M€-983k€410k▲ 142%
Financial income75/76B€24k€315€3k€909€2k▲ 137%
Recurring financial income75€24k€315€3k€909€2k▲ 137%
Non-recurring financial income76B€0-----
Financial charges65/66B€20k€63k€159k€181k€128k▼ 29.7%
Recurring financial charges65€20k€63k€159k€181k€128k▼ 29.7%
Profit (loss) for the period before taxes9903€-1.48M€-2.37M€-1.90M€-1.16M€285k▲ 124%
Income taxes67/77€-155€0-€-12k€0▲ 100%
Profit (loss) for the period9904€-1.48M€-2.37M€-1.90M€-1.15M€285k▲ 125%
Profit (loss) for the period to be appropriated9905€-1.48M€-2.37M€-1.90M€-1.15M€285k▲ 125%
Line20212022202320242025Change
Assets
Total assets20/58€4.79M€3.66M€3.02M€3.80M€4.31M▲ 13.3%
Formation expenses20€2k€772€0---
Fixed assets21/28€608k€1.04M€1.07M€1.81M€3.11M▲ 71.7%
Intangible fixed assets21€483k€852k€932k€1.70M€3.03M▲ 77.6%
Tangible fixed assets22/27€102k€101k€59k€37k€14k▼ 61.8%
Furniture and vehicles24€100k€89k€50k€32k€12k▼ 62.5%
Other tangible fixed assets26€2k€12k€9k€5k€2k▼ 57.0%
Assets under construction and advance payments27€0-----
Financial fixed assets28€22k€83k€75k€71k€71k=
Current assets29/58€4.18M€2.62M€1.96M€1.99M€1.19M▼ 40.0%
Amounts receivable within one year40/41€600k€215k€338k€845k€1.15M▲ 36.3%
Trade receivables40€311k€44k€188k€556k€672k▲ 20.9%
Other amounts receivable41€288k€171k€150k€289k€480k▲ 65.9%
Cash at bank and in hand54/58€3.50M€2.20M€1.20M€1.00M€9k▼ 99.1%
Deferred charges and accrued income490/1€78k€210k€417k€138k€32k▼ 77.1%
Equity and liabilities
Total equity and liabilities10/49€4.79M€3.66M€3.02M€3.80M€4.31M▲ 13.3%
Equity10/15€410k€-1.76M€-3.61M€-1.02M€-4k▲ 99.6%
Contributions10/11€150k€150k€150k€3.47M€3.47M=
Capital10€126k€126k€126k€270k€270k=
Issued capital100€126k€126k€126k€270k€270k=
Outside capital11€24k€24k€24k€3.20M€3.20M=
Share premium1100/10€24k€24k€24k€3.20M€3.20M=
Profit (loss) carried forward14€0€-2.37M€-4.27M€-5.42M€-5.14M▲ 5.3%
Investment grants15€260k€462k€505k€929k€1.66M▲ 79.0%
Amounts payable17/49€4.38M€5.42M€6.64M€4.82M€4.31M▼ 10.6%
Amounts payable after more than one year17€3.16M€3.57M€3.36M€1.40M€769k▼ 45.2%
Financial debts170/4€3.16M€3.57M€3.36M€1.40M€769k▼ 45.2%
Amounts payable within one year42/48€553k€1.29M€2.55M€2.85M€3.41M▲ 19.9%
Current portion of amounts payable after more than one year42€58k€72k€172k€162k€221k▲ 36.1%
Financial debts43-€743k€1.75M€2.00M€2.04M▲ 2.1%
Credit institutions430/8-€743k€1.75M€2.00M€1.69M▼ 15.4%
Other loans439----€350k-
Trade debts44€297k€261k€410k€525k€1.02M▲ 94.1%
Suppliers440/4€297k€261k€410k€525k€1.02M▲ 94.1%
Taxes, remuneration and social security45€198k€218k€218k€159k€130k▼ 18.5%
Taxes450/3€17k€10k€18k€2k€1k▼ 47.6%
Remuneration and social security454/9€181k€208k€200k€157k€129k▼ 18.1%
Accrued charges and deferred income492/3€660k€557k€722k€573k€130k▼ 77.3%
Line20212022202320242025Change
Profit (loss) for the period9904€-1.48M€-2.37M€-1.90M€-1.15M€285k▲ 125%
+ Depreciation and write-downs630€1.51M€893k€827k€682k€448k▼ 34.3%
Operating cash flow (approximation)€28k€-1.47M€-1.08M€-470k€732k▲ 256%
Investment in fixed assets (approximation)-€-1.32M€-856k€-1.43M€-1.75M▼ 22.3%
Change in cash-€-1.30M€-999k€-198k€-994k▼ 403%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Sign in to download as CSV

Timeline · acts, filings and financial milestones

Next filing, fiscal year 2026, expected by 31-07-2027
2026
01-09
State Gazette act Reappointments: Dx Orange, Noshaq and 2 others
Resignations: Dx Orange, NOSHAQ PARTNERS and 2 others · Appointments: NOSHAQ PARTNERS, DEHOUSSE Stéphane and 2 others · Permanent representative: WALLEMACQ Hugues37 facts ▸
  • General meeting, 28-08-2026
  • Other statement, 12-08-2026
  • Other statement, 12-08-2026
  • Declaration, connaissance des rapports, dispense de lecture intégrale
  • Other statement, annexes des rapports
  • Share class, conversion, A
  • Share class, D, creation
  • Capital
  • Other statement, 12-08-2026
  • Other statement, 12-08-2026
  • Auditor report, 23-07-2026, aucune constatation significative concernant la description, l'évaluation et les modes d'évaluation; valeur de l'apport correspond au moins au pair…
  • Capital increase, €378.000
  • +25 further facts in this act
03-07
NBB filing Annual accounts filed
fiscal year 2025 · full schema
02-02
NBB filing Annual accounts filed
fiscal year 2024 · full schema · 186 days late
2025
31-12
Financial Back to profitnet €285k
Net result €285k after 7 loss-making years.
2024
05-08
NBB filing Annual accounts filed
fiscal year 2023 · full schema · 5 days late
2023
10-07
NBB filing Annual accounts filed
fiscal year 2022 · full schema
2022
31-12
Financial Weakest financial yearnet €-2.37M
Net result drops to €-2.37M, the lowest in the series; recovery starts the following year.
06-09
NBB filing Annual accounts filed
fiscal year 2021 · full schema · 37 days late
2021
31-12
Financial Equity above €200kEq €410k
Equity rises from €-494k to €410k.
29-07
NBB filing Annual accounts filed
fiscal year 2020 · full schema
2020
15-07
NBB filing Annual accounts filed
fiscal year 2019 · full schema
2019
31-12
Financial Equity above €200kEq €226k
Equity rises from €-1.06M to €226k.
23-07
NBB filing Annual accounts filed
fiscal year 2018 · full schema
2018
06-11
NBB filing Annual accounts filed
fiscal year 2017 · full schema · 98 days late
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 16 acts read
About the unread acts

Of the 16 Belgian State Gazette acts we know for this company, 1 has been read. The other 15 have not been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Directors · office · real estate

Directors
under verification, last change in 2026
This board is reconstructed from a single act (26357174). A Gazette act generally publishes only CHANGES, not a full roll call, so directors unchanged since then may be missing here. The KBO register holds the complete list of function holders.
Ludovic WOUTERS
Class B director · since 01-09-2026
Current
NOSHAQ PARTNERS
Class A director · since 01-09-2026 · Legal entity · perm. rep.: WALLEMACQ Hugues
Current
Stéphane DEHOUSSE
Class B director · since 01-09-2026
Current
Wim Vos
Administrateur d · since 01-09-2026
Current
NOSHAQ
Director · since 03-07-2026 · Legal entity · perm. rep.: WALLEMACQ Hugues
Current
01-09-2026 Ludovic WOUTERS: Appointed as Class B director
01-09-2026 NOSHAQ PARTNERS: Resigned as Director
01-09-2026 NOSHAQ PARTNERS: Appointed as Class A director
01-09-2026 Stéphane DEHOUSSE: Appointed as Class B director
01-09-2026 Wim Vos: Appointed as Administrateur d
Full history in the Timeline (9 changes) →
Not every act has been read: a resignation may be missing here
15 of this company's 16 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Liège · 1 establishment unit since 2016
seat establishment The establishment unit on the map
Ground area
1.9 ha
Parcel 62042B0366/00B003, Wallonia. Linked by address, not a title deed.
43 companies at this address See who is registered here
1 establishment unit
Radiomics
Boulevard de Patience et Beaujonc 3, 4000 LiègeScientific research and development
since 20162.256.770.029
1 parcel
Wallonia 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
62042B0366/00B003 Wallonia 1.9 ha - -
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Articles of association

Who signs
“ARTICLE 19 - REPRESENTATION ACTES ET ACTIONS JUDICIAIRES Sauf délégations ou pouvoirs particuliers et sans préjudice aux délégations visées à l'article précédent, la société est valablement représentée en général, et notamment en tous recours judiciaires et administratifs tant en demandant qu'en…”
Full text

ARTICLE 19 - REPRESENTATION ACTES ET ACTIONS JUDICIAIRES Sauf délégations ou pouvoirs particuliers et sans préjudice aux délégations visées à l'article précédent, la société est valablement représentée en général, et notamment en tous recours judiciaires et administratifs tant en demandant qu'en défendant, ainsi qu'à tous actes et procurations, y compris ceux où intervient un fonctionnaire public ou un officier ministériel, par un Administrateur B agissant conjointement avec un Administrateur A ou avec un Administrateur D, lesquels n'auront, en aucun cas, à justifier d'une décision préalable du conseil d'administration. Toutefois, si les actionnaires d’une classe ont souhaité ne pas être représentés au conseil d'administration, la société sera valablement représentée par deux administrateurs agissant conjointement. Les expéditions et extraits des décisions du conseil d'administration, ainsi que celles des résolutions de l'assemblée générale, seront signés conformément à l'alinéa qui précède. En ce qui concerne la gestion journalière, la société sera représentée valablement par le ou les administrateurs-délégués, directeurs et agents auxquels cette gestion aura été déléguée et ce pour toutes les opérations qui peuvent être comprises dans la gestion journalière. Les mandataires spéciaux disposeront du pouvoir de représentation dans le cadre de leur compétence.

Annual meeting
Third Friday of June at 19:00
Purpose
La recherche et développement (analyse d'image, logiciels, médicaments, identification de nouvelles molécules (naturelles par exemple de plantes médicinales ou synthétiques, y…
Full purpose (12 activities)
  1. La recherche et développement (analyse d'image, logiciels, médicaments, identification de nouvelles molécules (naturelles par exemple de plantes médicinales ou synthétiques, y compris des anticorps mono ou polyclonaux d'origine humaine ou animale (souris, rat, chien, chevaux, Iamas…), nouveaux moyens diagnostiques (biomarqueurs d'imagerie et biomarqueurs solubles et moléculaires), nouveaux traitements (médicamenteux ou liés à la radiothérapie ou à l'immunothérapie...), les avis et expertises, l'éducation (y compris les conférences, l'«eLearning » et « shared decision making ») , la communication et l'organisation d'évènements dans le domaine scientifique, en particulier (mais pas exclusivement) dans le domaine de sciences de la vie
  2. La recherche d'investisseurs et de collaborateurs potentiels se rapportant directement ou indirectement à son objet social ou susceptibles de favoriser son développement, par l'organisation d'évènements et ou des contacts en Belgique et à l'étranger
  3. Prendre des participations dans d'autres sociétés ou entreprises existantes ou à créer, que ce soit en Belgique ou à l'étranger, dont l'objet social serait semblable ou analogue au sien ou de nature à favoriser son objet social, par voie d'apport en espèces ou en nature, de fusion, de souscription, de participation, d'intervention financière ou autrement
  4. Faire toutes opérations commerciales, industrielles et financières, immobilières et mobilières, se rapportant directement ou indirectement à son objet social ou susceptibles de favoriser son développement
  5. Prendre la direction et le contrôle des sociétés affiliées ou filiales, et leur prodiguer des avis
  6. Exercer ses activités en tant qu'associé et/ou gérant d'une société civile professionnelle, multi professionnelle ou interprofessionnelle, ayant éventuellement adopté la forme juridique d'une société commerciale et dont l'objet social est semblable, similaire ou analogue au sien
  7. Accomplir toutes opérations commerciales et industrielles, financières, mobilières ou immobilières utiles pour la réalisation de l'objet social, y compris crédits et financements ou autres opérations avec Banques, Instituts de crédits et sociétés, en leur donnant les garanties opportunes
  8. Prendre des participations et intérêts, directement ou indirectement, dans des sociétés qui développent des activités similaires, équivalentes ou connexes à sa propre activité, soit en Belgique, que dans les autres territoires, liquider ou céder des participations
  9. Être gérant d'autres sociétés et acheter des usufruits dans le sens le plus large du terme
  10. S'intéresser par voie de souscription, de participation, d'acquisition, de cession, d'apports ou de fusion ou autrement, dans toutes sociétés ou entreprises, belges ou étrangères, créées ou à créer, dont l'objet serait analogue ou connexe au sien, ou de nature à favoriser son activité dans le cadre de son objet
  11. Prêter à toutes sociétés et/ou personnes physiques et se porter caution pour elles, même hypothécairement
  12. Louer ou sous louer, acquérir des droits réels ou la pleine pr0priété de tout immeuble dans le but soit d'y établir son siège social, un siège d'exploitation ou d'y loger ses dirigeants et les membres de leur famille à titre de résidence principale ou secondaire, en Belgique ou à l'étranger
Other provisions of the articles (47)
  • Legal form clause: ONCORADIOMICS
  • Registered office clause
  • Capital: €1.598.967,56
  • Share class: En cas de cession d’actions entre actionnaires ou d'émission d’actions nouvelles en faveur d'actionnaires existants, les actions cédées ou émises seront (re)cla…
  • Share class
  • Authorised capital: B, Cette autorisation pourra être renouvelée conformément aux dispositions légales.
  • Authorised capital
  • Other provision: capital modification, par décision de l'assemblée générale des actionnaires statuant dans les conditions fixées par la loi
  • Other provision: sur l'ensemble des actions dont l'actionnaire est titulaire, conseil d'administration
  • Other provision: l'actionnaire reste tenu de la différence ou profite de l'excédent, le conseil d'administration peut prononcer la déchéance de l'actionnaire et faire vendre ses…
  • Share register: tout actionnaire peut prendre connaissance, nominatifs
  • Share register
  • Transfer restriction
  • Financial instrument: obligations, conseil d'administration
  • Financial instrument
  • Board rule (4)
  • Board rule: sauf décision contraire de l'assemblée générale, l'administrateur désigné dans les conditions ci-dessus est nommé pour le temps nécessaire à l'achèvement du man…
  • Board rule: présidence et réunions du conseil, siège social sauf accord unanime
  • Board rule: quorum et délibérations du conseil, au moins la moitié des membres présents ou représentés
  • Board rule: majorité et décisions du conseil, majorité simple des voix
  • Board rule: tous les actes contribuant à la réalisation de l'objet, pouvoirs du conseil
  • Auditor rule: contrôle et nomination des commissaires, fixée par l'assemblée générale selon les normes de l'Institut des Réviseurs d'Entreprises
  • General meeting rule: composition et pouvoirs de l'assemblée générale, tous les propriétaires d'actions ayant droit de voter
  • General meeting rule: convocations, conformément à la loi, notamment par email
  • General meeting rule: admission à l'assemblée, propriétaires d'actions nominatives
  • General meeting rule: participation à distance, moyen de communication électronique mis à disposition par la société
  • General meeting rule: assemblée générale écrite, unanimité
  • General meeting rule: tout propriétaire de titres peut se faire représenter par un mandataire, représentation à l'assemblée
  • Other statement (10)
  • Profit allocation: affectation du solde sera opérée librement, sur proposition du conseil d'administration, par l'assemblée générale, prélèvement d'un vingtième au moins, affecté…
  • Dissolution rule: A moins que le conseil d'administration propose la dissolution de la société, il expose dans un rapport spécial, tenu à la disposition des actionnaires au siège…
  • Liquidation rule: L'assemblée générale détermine les pouvoirs et la rémunération éventuelle du ou des liquidateurs, un ou de plusieurs liquidateurs nommés par l'assemblée général…
  • Liquidation distribution: Le surplus éventuel de l'actif sera réparti selon les dispositions d'une convention d'actionnaires, Si les actions ne se trouvent pas libérées dans une mesure é…
  • Other statement: Ils peuvent toutefois également communiquer une adresse électronique aux fins de communiquer avec la société, Election of domicile
  • 1 more provision in the deed

Structure & network

Connections & network

6 connected companies
Linked via shared directors
TRAXIO
via Wim Vos · Director
former→
former→
VAB Rijschool
via Wim Vos · Director
former→
GALLER HOLDING
Shared director
→
Show 2 more companies with a shared director
ID CAMPUS ASBL
Shared director
→
VentureLab
Shared director
→

Capital and shareholders

Capital over the years
  1. 01-09-2026 Capital increase of 378,000 EUR · to 648,427.56 EUR · 72,411 new shares
  2. 01-09-2026 Capital increase of 100,000 EUR · to 748,427.56 EUR · 55,552 new shares
  3. 01-09-2026 Capital increase of 850,540 EUR · to 1,598,967.56 EUR · 472,502 new shares

Public money · subsidies and aid

European Union, budget

2021 to 2022 · 3 entries · 602,662 EUR in total
Year Entries awarded
2022 1 202,662 EUR
2021 2 400,000 EUR
Projects
TIGER - PROOF OF PRINCIPLE OF THE BEST-IN-CLASS THERAPEUTIC MRNA CANCER VACCINE
Horizon Europe · 01-02-2021 to 31-07-2025 · 400,000 EUR
EUCAIM - EUROPEAN FEDERATION FOR CANCER IMAGES
Digital Europe Programme · 01-01-2023 to 31-12-2026 · 202,662 EUR

European research

4 projects · 3,104,479 EUR EU contribution
Programmes
Horizon 2020
4 entries · 3,104,479 EUR
Projects
The RapiD and SecuRe AI enhAnced DiaGnosis, Precision Medicine and Patient EmpOwerment Centered Decision Support System for Coronavirus PaNdemics
Horizon 2020 · participant · 01-10-2020 to 31-03-2024 · 1,730,859 EUR · DRAGON
A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology
Horizon 2020 · participant · 01-10-2017 to 31-03-2022 · 501,120 EUR · PREDICT
A European Cancer Image Platform Linked to Biological and Health Data for Next-Generation Artificial Intelligence and Precision Medicine in Oncology
Horizon 2020 · participant · 01-10-2020 to 30-09-2025 · 472,500 EUR · EuCanImage
Proof of Principle of the best-in-class therapeutic mRNA cancer vaccine
Horizon 2020 · participant · 01-02-2021 to 31-07-2025 · 400,000 EUR · TIGER

Recognitions · licences · registrations

Legal Entity Identifier

984500MDE880D7FACF28
live in the LEI register

Similar companies · same sector, comparable size

Of 762 companies in sector 72101 we hold annual accounts for 482. 328 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification
Legal formPublic limited company
Founded19-09-2016
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
72109Other research and development on natural sciences

Scores and ratios are computed by Checked and are not a credit decision.